Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement

European Respiratory Journal

Volumn 44, Issue 1, 2014, Pages 23-63

  Lange, Christoph ^a   Abubakar, Ibrahim ^a   Alffenaar, Jan Willem C ^a   Bothamley, Graham ^a   Caminero, Jose A ^a   Carvalho, Anna Cristina C ^a   Chang, Kwok Chiu ^a   Codecasa, Luigi ^a   Correia, Ana ^a   Crudu, Valeriu ^a   Davies, Peter ^a   Dedicoat, Martin ^a   Drobniewski, Francis ^a   Duarte, Raquel ^a   Ehlers, Cordula ^a   Erkens, Connie ^a   Goletti, Delia ^a   Günther, Gunar ^a   Ibraim, Elmira ^a   Kampmann, Beate ^a   Kuksa, Liga ^a   De Lange, Wiel ^a   Van Leth, Frank ^a   Van Lunzen, Jan ^a   Matteelli, Alberto ^a   Menzies, Dick ^a   Monedero, Ignacio ^a   Richter, Elvira ^a   Rüsch Gerdes, Sabine ^a   Sandgren, Andreas ^a   Scardigli, Anna ^a   Skrahina, Alena ^a   Tortoli, Enrico ^a   Volchenkov, Grigory ^a   Wagner, Dirk ^a   Van Der Werf, Marieke J ^a   Williams, Bhanu ^a   Yew, Wing Wai ^a   Zellweger, Jean Pierre ^a   Cirillo, Daniela Maria ^a   more..

^a Tuberculosis Center Borstel   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PRETOMANID; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CHILD CARE; DEPRESSION; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FOLLOW UP; GASTRITIS; GASTROINTESTINAL DISEASE; GENE MUTATION; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; GOUT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPOTHYROIDISM; INFECTION CONTROL; INFECTION PREVENTION; INSOMNIA; LIVER TOXICITY; LUNG RESECTION; MEDICAL DECISION MAKING; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OTOTOXICITY; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; SKIN DISCOLORATION; TENDINITIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; CASE MANAGEMENT; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASE CONTROL; CONSENSUS; DISEASE FREE SURVIVAL; DISEASE MANAGEMENT; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GEOGRAPHY; INFECTIOUS DISEASE MEDICINE; PUBLIC HEALTH; RECURRENT DISEASE; STANDARDS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CASE MANAGEMENT; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; CONSENSUS; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; EUROPE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GEOGRAPHY; HUMANS; INFECTIOUS DISEASE MEDICINE; PUBLIC HEALTH; RECURRENCE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84902185616     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00188313     Document Type: Article

References (269)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260.
2. World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland, 2013.
3. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
4. Skrahina A, Hurevich H, Zalutskaya A, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 2013; 91: 36-45.
5. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
6. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
7. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe. Stockholm, European Centre for Disease Prevention and Control, 2013.
8. Lassen O. On the curability of open pulmonary tuberculosis. Acta Tuberc Scand 1950; 26: 169-170.
9. East African/British Medical Research Council. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977; 116: 3-8.
10. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. www.who.int/tb/challenges/mdr/programmatic- guidelines-for-mdrtb/en/Datelastaccessed:December12,2012.Datelastupdated:2011.
11. Soldatou A, Davies EG. Respiratory virus infections in the immunocompromised host. Paediatr Respir Rev 2003; 4: 193-204.
12. Diel R, Rutz S, Castell S, et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151.
13. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
14. Greco S, Girardi E, Navarra A, et al. Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 2006; 61: 783-790.
15. Food and Drug Administration. FDA news release. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm333695.htmDatelastaccessed:2012.Datelastupdated: December31,2012.
16. World Health Organization. Roadmap to prevent and combat drug-resistant tuberculosis. www.euro.who.int/-data/assets/pdf-file/0014/152015/e95786. pdfDatelastupdated:2011.
17. European Centre for Disease Control and Prevention. Management of contacts of MDR TB and XDR TB patients. Stockholm, Sweden, 2012.
18. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision. Geneva, Switzerland, 2013.
19. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-425.
20. Udwadia ZF, Amale RA, Ajbani KK, et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-581.
21. Pai M, OBrien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 2008; 29: 560-568.
22. World Health Organization. Stop TB Department of WHO technical consultation in Geneva on 21-22 March 2012. www.who.int/tb/challenges/xdr/ xdrconsultation/en/index.htmlDatelastaccessed:2012.Datelastupdated:March,2012.
23. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva, 2008.
24. World Health Organization. Management of MDR-TB: a field guide: a companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI). http://apps.who.int/iris/handle/10665/44163?locale5esDatelastaccessed: December13,2012.Datelastupdated:2009.
25. International Union Against Tuberculosis and Lung Diseases. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. IUTLD, Paris, 2013.
26. Migliori GB, Zellweger JP, Abubakar I, et al. European Union Standards for Tuberculosis Care. Eur Respir J 2012; 39: 807-819.
27. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care. ISTC, The Hague, 2009.
28. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010; 36: 925-949.
29. Centers of Diseases Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005; 54: 1-47.
30. Targeted tuberculin testing and treatment of latent tuberculosis infection
31. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. www.who.int/tb/publications/2011/mdr-report-2011/en/Datelastaccessed: December12,2012.Datelastupdated:March23,2011.
32. World Health Organization. Global tuberculosis report 2012. Geneva, Switzerland, 2012.
33. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158-163.
34. Liang L, Wu Q, Gao L, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax 2012; 67: 632-638.
35. Shen X, DeRiemer K, Yuan ZA, et al. Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors. Int J Tuberc Lung Dis 2009; 13: 253-259.
36. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-1417.
37. Shin SS, Keshavjee S, Gelmanova IY, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182: 426-432.
38. Brewer TF, Choi HW, Seas C, et al. Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment. PLoS One 2011; 6: e25861.
39. Otero L, Krapp F, Tomatis C, et al. High prevalence of primary multidrug resistant tuberculosis in persons with no known risk factors. PLoS One 2011; 6: e26276.
40. Balabanova Y, Radiulyte B, Davidaviciene E, et al. Risk factors for drug-resistant tuberculosis patients in Lithuania, 2002-2008. Eur Respir J 2012; 39: 1266-1269.
41. Zhao Y, Xu S,Wang L, et al. National survey of drug-resistant tuberculosis in China.NEngl JMed 2012; 366: 2161-2170.
42. van der Werf MJ, Langendam MW, Huitric E, et al. Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis. Eur Respir J 2012; 39: 1511-1519.
43. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 Global Report on Surveillance and response. Geneva, Switzerland, 2010.
44. Lan NTN, Lien HTK, Tung LB, et al. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis 2003; 9: 1633-1635.
45. Bate R, Jensen P, Hess K, et al. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. Int J Tuberc Lung Dis 2013; 17: 308-311.
46. Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-1473.
47. Royce S, Falzon D, van Weezenbeek C, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis 2013; 17: 511-513.
48. Stuckler D, Basu S, McKee M, et al. Mass incarceration can explain population increases in TB and multidrugresistant TB in European and central Asian countries. Proc Natl Acad Sci USA 2008; 105: 13280-13285.
49. Shin SS, Keshavjee S, Gelmanova IY, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182: 426-432.
50. Minion J, Gallant V, Wolfe J, et al. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS One 2013; 8: e53466.
51. Hu Y, Mathema B, Jiang W, et al. Transmission pattern of drug-resistant tuberculosis and its implication for tuberculosis control in eastern rural China. PLoS One 2011; 6: e19548.
52. Fox GJ, Dobler CC, Marks GB. Active case finding in contacts of people with tuberculosis. Cochrane Database Syst Rev 2011; 9: CD008477.
53. Behr MA, Hopewell PC, Paz EA, et al. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med 1998; 158: 465-469.
54. Cox H, van Cutsem G. Household screening and multidrug-resistant tuberculosis. Lancet 2011; 377: 103-104.
55. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrugresistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377: 147-152.
56. Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle. Tuber Lung Dis 1992; 73: 73-76.
57. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000; 152: 247-263.
58. Poulsen A. Some clinical features of tuberculosis. 1. Incubation period. Acta Tuberc Scand 1950; 24: 311-346.
59. Fraser A, Paul M, Attamna A, et al. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2009; 2: CD005435.
60. van der Werf MJ, Langendam MW, Sandgren A, et al. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012; 16: 288-296.
61. Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109: 765-771.
62. Denholm JT, Leslie DE, Jenkin GA, et al. Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995-2010. Int J Tuberc Lung Dis 2012; 16: 1320-1325.
63. Two simultaneous outbreaks of multidrug-resistant tuberculosis - Federated States of Micronesia, 2007-2009
64. van der Werf MJ, Sandgren A, Manissero D. Management of contacts of multidrug-resistant tuberculosis patients in the European Union and European Economic Area. Int J Tuberc Lung Dis 2012; 16: 426.
65. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011; 12: 31-38.
66. Falzon D, Jaramillo E, Wares F, et al. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis 2013; 13: 690-697.
67. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. www.who.int/tb/ publications/2009/9789241598323/en/Datelastaccessed:December13,2012. Datelastupdated:2009.
68. Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54: 1-141.
69. TB CARE I. Infection Control, www.tbcare1.org/publications/toolbox/ic
70. Drobniewski F, Balabanova Y, Nikolayevsky V, et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 2005; 293: 2726-2731.
71. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
72. Riley RL, Mills CC, Nyka W, et al. Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am J Epidemiol 1995; 142: 3-14.
73. Riley RL, Mills CC, OGrady F, et al. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 1962; 85: 511-525.
74. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976; 57: 275-299.
75. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444-449.
76. Escombe AR, Moore DA, Gilman RH, et al. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med 2008; 5: e188.
77. Fennelly KP, Jones-Lopez EC, Ayakaka I, et al. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2012; 186: 450-457.
78. Fitzwater SP, Caviedes L, Gilman RH, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis 2010; 51: 371-378.
79. Sepkowitz KA. How contagious is tuberculosis. Clin Infect Dis 1996; 23: 954-962.
80. Menzies D. Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Infect Control Hosp Epidemiol 1997; 18: 582-586.
81. Coffey CC, Lawrence RB, Campbell DL, et al. Fitting characteristics of eighteen N95 filtering-facepiece respirators. J Occup Environ Hyg 2004; 1: 262-271.
82. US Department of Labor Occupational and Health Safety Standards 1910 AppA: Fit Testing Procedures. Washington, Department of Labor, 2004.
83. Dharmadhikari AS, Mphahlele M, Stoltz A, et al. Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med 2012; 185: 1104-1109.
84. Bock NN, Jenssen PA, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196: Suppl. 1, S108-S113.
85. World Health Organization. Natural ventilation for infection control in health-care settings. WHO guideline 2009. Geneva, Switzerland, 2009.
86. Streifel AJ. Design and maintenance of hospital ventilation systems and prevention of airborne nosocomial infections. In: Mayhall CG, ed. Hospital Epidemiology and Infection Control. 2nd Edn. Philadelphia, Lippincott Williams and Wilkins, 1999; pp. 1211-1221.
87. Centers for Disease Control and Prevention. Environmental Control for Tuberculosis: Basic Upper-Room Ultraviolet Germicidal Irradiation. Atlanta, Guidelines for Healthcare Settings, 2009.
88. Xu P, Kujundzic E, Peccia J, et al. Impact of environmental factors on efficacy of upper-room air ultraviolet germicidal irradiation for inactivating airborne mycobacteria. Environ Sci Technol 2005; 39: 9656-9664.
89. Lee K, Slavcev A, Nicas M. Respiratory protection against Mycobacterium tuberculosis: quantitative fit test outcomes for five type N95 filtering-facepiece respirators. J Occup Environ Hyg 2004; 1: 22-28.
90. Balabanova Y, Drobniewski F, Nikolayevskyy V, et al. An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia. PLoS One 2009; 4: e7129.
91. World Health Organization. The use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Geneva, Switzerland, 2007.
92. Pfyffer GE, Bonato DA, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186.
93. Rusch-Gerdes S, Pfyffer GE, Casal M, et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692.
94. Kruuner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 811-818.
95. Kim SJ, Espinal MA, Abe C, et al. Is second-line anti-tuberculosis drug susceptibility testing reliable. Int J Tuberc Lung Dis 2004; 8: 1157-1158.
96. Sulochana S, Venkataraman P, Paramasivan CN. Evaluation of various methods of susceptibility to ofloxacin in strains of Mycobacterium tuberculosis. Indian J Med Res 1999; 110: 186-189.
97. Somasundaram S, Paramasivan NC. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy 2006; 52: 190-195.
98. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-1025.
99. Rodrigues C, Jani J, Shenai S, et al. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis 2008; 12: 1449-1455.
100. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 2011; 66: 1417-1430.
101. Traore H, Fissette K, Bastian I, et al. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis 2000; 4: 481-484.
102. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29.
103. Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
104. Laurenzo D, Mousa SA. Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop 2011; 119: 5-10.
105. Larsen MH, Vilcheze C, Kremer L, et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 2002; 46: 453-466.
106. van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
107. Bottger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-1134.
108. Plinke C, Rusch-Gerdes S, Niemann S. Significance of mutations in embB codon 306 for prediction of ethambutol resistance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2006; 50: 1900-1902.
109. Miotto P, Cabibbe AM, Mantegani P, et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 2012; 40: 690-698.
110. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-1330.
111. Aubry A, Pan XS, Fisher LM, et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004; 48: 1281-1288.
112. Von Groll A, Martin A, Jureen P, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53: 4498-4500.
113. Via LE, Cho SN, Hwang S, et al. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol 2010; 48: 402-411.
114. Georghiou SB, Magana M, Garfein RS, et al. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012; 7: e33275.
115. Van Deun A, Aung KJ, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-2640.
116. Crudu V, Stratan E, Romancenco E, et al. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 2012; 50: 1264-1269.
117. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-1505.
118. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, World Health Organization, 2011.
119. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40: 442-447.
120. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
121. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-612.
122. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
123. Caminero JA. A tuberculosis guide for specialist physicians. Paris, International Union Against Tuberculosis and Lung Disease, 2004.
124. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006; 10: 829-837.
125. Caminero JA, Matteelli A, Lange C. Treatment of TB. In: Lange C, Migliori GB, eds. Tuberculosis. Eur Respir Monogr 2012; 58: 154-166.
126. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
127. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25: 928-936.
128. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-569.
129. van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-140.
130. Jonsson S, Davidse A, Wilkins J, et al. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother 2011; 55: 4230-4237.
131. Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb) 2012; 92: 1-8.
132. Donald PR, Sirgel FA, Venter A, et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2001; 5: 533-538.
133. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38: 1538-1544.
134. Donomae I. Capreomycin in the treatment of pulmonary tuberculosis. Ann NY Acad Sci 1966; 135: 1011-1038.
135. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-857.
136. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-894.
137. Lee HW, Kim DW, Park JH, et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1161-1166.
138. Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2002; 82: 91-96.
139. Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 2001; 33: 466-469.
140. Gopal M, Padayatchi N, Metcalfe JZ, et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 1001-1007.
141. Alffenaar JW, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010; 49: 559-565.
142. McGee B, Dietze R, Hadad DJ, et al. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2009; 53: 3981-3984.
143. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics- pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55: 24-34.
144. Gumbo T, Dona CS, Meek C, et al. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53: 3197-3204.
145. Rodriguez JC, Cebrian L, Lopez M, et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004; 53: 441-444.
146. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-582.
147. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.
148. Wallis RS, Jakubiec W, Kumar V, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011; 55: 567-574.
149. Cynamon MH, Zhang Y, Harpster T, et al. High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 1999; 43: 2922-2924.
150. Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 139-145.
151. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrugresistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
152. Chang KC, Yew WW, Tam CM, et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4097-4104.
153. Jordan TS, Cullen D, Davies PD. A centralised electronic Multidrug-Resistant Tuberculosis Advisory Service: the first 2 years. Int J Tuberc Lung Dis 2012; 16: 950-954.
154. Sotgiu G, Centis R, DAmbrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
155. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrugresistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.
156. Chang KC, Yew WW, Cheung SW, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2013; 57: 3445-3449.
157. Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68: 284-293.
158. Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-298.
159. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
160. Blasi F, Dara M, van der Werf MJ, et al. Supporting TB clinicians managing difficult cases: the ERS/WHO Consilium. Eur Respir J 2013; 41: 491-494.
161. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J 2011; 37: 441-462.
162. Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010; 375: 2100-2109.
163. Caminero JA, Matteelli A, Loddenkemper R. Tuberculosis: are we making it incurable. Eur Respir J 2013; 42: 5-8.
164. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205: Suppl. 2, S241-249.
165. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013; 12: 388-404.
166. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
167. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954.
168. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
169. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrugresistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
170. European Medicines Agency. European Medicines Agency recommends two new treatment options for tuberculosis. www.ema.europa.eu/ema/index.jsp?curl5pages/ news-and-events/news/2013/11/news-detail-001972.jsp& mid5WC0b01ac058004d5c1Datelastaccessed:December29,2013.Datelastupdated: November22,2013.
171. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
172. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drugresistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 623-625.
173. Kempker RR, Vashakidze S, Solomonia N, et al. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 157-166.
174. Toman K. Tuberculosis case-finding and chemotherapy. Questions and answers. Geneva, World Health Organization, 1979.
175. Rieder HL. Interventions for tuberculosis control and elimination. Paris, International Union Against Tuberculosis and Lung Disease, 2002; pp. 1-251.
176. Fox W. The current status of short-course chemotherapy. Tubercle 1979; 60: 177-190.
177. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279.
178. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary
179. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable. Eur Respir J 2012; 40: 9-11.
180. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
181. Leung EC, Yew WW, Leung CC, et al. Shorter treatment duration for selected patients with multidrug-resistant tuberculosis. Eur Respir J 2011; 38: 227-230.
182. Nunn A. The evaluation of a standardised treatment regimen of anti-tuberculosis drugs for patients with multidrug- resistant tuberculosis (MDR-TB), www.controlled-trials.com/ISRCTN78372190Datelastupdated:November
183. Brown J, Dooley D, Backer H. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd Edn. San Francisco, Curry International Tuberculosis Center, 2011.
184. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14: 275-281.
185. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
186. Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infect Ther 2012; 10: 475-486.
187. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 2010; 24: 655-667.
188. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-627.
189. Talbert Estlin KA, Sadun AA. Risk factors for ethambutol optic toxicity. Int Ophthalmol 2010; 30: 63-72.
190. Xu HB, Jiang RH, Li L, et al. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis 2012; 16: 358-363.
191. McDonnell ME, Braverman LE, Bernardo J. Hypothyroidism due to ethionamide. N Engl JMed 2005; 352: 2757-2759.
192. Fortun J, Martin-Davila P, Navas E, et al. Cambios en la Epidemiología de la Tuberculosis: la Influencia de los movimientos migratorios internacionales [Changes in the epidemiology of tuberculosis: the influence of international migration flows]. Enferm Infecc Microbiol Clin 2011; 29: 654-659.
193. Pedrazzoli D, Fulton N, Anderson L, et al. Tuberculosis in the UK: 2012 report. London, Health Protection Agency, 2012.
194. Bonacci RA, Cruz-Hervert LP, Garcia-Garcia L, et al. Impact of cigarette smoking on rates and clinical prognosis of pulmonary tuberculosis in Southern Mexico. J Infect 2013; 66: 303-312.
195. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-250.
196. Perez-Guzman C, Vargas MH, Quinonez F, et al. A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 2005; 127: 643-651.
197. van der Watt JJ, Harrison TB, Benatar M, et al. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. Int J Tuberc Lung Dis 2011; 15: 722-728.
198. Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.
199. Diacon AH, Maritz JS, Venter A, et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis 2010; 29: 1561-1565.
200. Wejse C, Gustafson P, Nielsen J, et al. TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008; 40: 111-120.
201. Malla P, Kanitz EE, Akhtar M, et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One 2009; 4: e8313.
202. Heller T, Lessells RJ, Wallrauch CG, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010; 14: 420-426.
203. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
204. Brust JC, Shah NS, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012; 16: 998-1004.
205. Brannan JW. Home treatment of tuberculosis by means of hospital dispensaries. Trans Am Climatol Assoc 1904; 20: 149-163.
206. Toczek A, Cox H, du Cros P, et al. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2013; 17: 299-307.
207. Goemaere E, Ford N, Berman D, et al. XDR-TB in South Africa: detention is not the priority. PLoSMed 2007; 4: e162.
208. Bekker LG, Wood R. Community-based management of multidrug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis 2010; 14: 379.
209. Lutge EE, Wiysonge CS, Knight SE, et al. Material incentives and enablers in the management of tuberculosis. Cochrane Database Syst Rev 2012; 1: CD007952.
210. Cayla JA, Orcau A. Control of tuberculosis in large cities in developed countries: an organizational problem. BMC Med 2011; 9: 127.
211. Hales CM, Heilig CM, Chaisson R, et al. The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc 2013; 10: 18-25.
212. Zar HJ, Connell TG, Nicol M. Diagnosis of pulmonary tuberculosis in children: new advances. Expert Rev Anti Infect Ther 2010; 8: 277-288.
213. Starke JR. Pediatric tuberculosis: time for a new approach. Tuberculosis (Edinb) 2003; 83: 208-212.
214. Dominguez J, De Souza-Galvao M, Ruiz-Manzano J, et al. T-cell responses to the Mycobacterium tuberculosisspecific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagn Microbiol Infect Dis 2009; 63: 43-51.
215. Marais BJ, Hesseling AC, Gie RP, et al. The bacteriologic yield in children with intrathoracic tuberculosis. Clin Infect Dis 2006; 42: e69-e71.
216. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
217. Seddon JA, Hesseling AC, Godfrey-Faussett P, et al. Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study. BMC Infect Dis 2013; 13: 392.
218. Feja K, McNelley E, Tran CS, et al. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr Infect Dis J 2008; 27: 907-912.
219. Flood J, Oh P, Lewis B, et al. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293: 2732-2739.
220. Mendez Echevarria A, Baquero Artigao F, Garcia Miguel MJ, et al. Tuberculosis mutirresistente en la edad pediatrica [Multidrug-resistant tuberculosis in the pediatric age group]. An Pediatr (Barc) 2007; 67: 206-211.
221. Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117: 2022-2029.
222. Seddon JA, Hesseling AC, Willemse M, et al. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54: 157-166.
223. Fairlie L, Beylis NC, Reubenson G, et al. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis 2011; 11: 28.
224. Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109: 765-771.
225. Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 321-328.
226. Kritski AL, Marques MJ, Rabahi MF, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331-335.
227. Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 449-456.
228. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis J 2011; 30: 501-505.
229. Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186: 953-964.
230. Palacios E, Dallman R, Munoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009; 48: 1413-1419.
231. Shin S, Guerra D, Rich M, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis 2003; 36: 996-1003.
232. Lessnau KD, Qarah S. Multidrug-resistant tuberculosis in pregnancy: case report and review of the literature. Chest 2003; 123: 953-956.
233. Tabarsi P, Moradi A, Baghaei P, et al. Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy. Int J Tuberc Lung Dis 2011; 15: 547-550.
234. Donald PR, Doherty E, Van Zyl FJ. Hearing loss in the child following streptomycin administration during pregnancy. Cent Afr J Med 1991; 37: 268-271.
235. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42: 1336-1339.
236. Good JT Jr, Iseman MD, Davidson PT, et al. Tuberculosis in association with pregnancy. Am J Obstet Gynecol 1981; 140: 492-498.
237. Getahun H, Sculier D, Sismanidis C, et al. Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis 2012; 205: Suppl. 2, S216-S227.
238. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196: Suppl. 1, S86-S107.
239. Matteelli A, Richardson MD, Sotgiu G, et al. Multidrug- and extensively drug-resistant TB in persons living with HIV. Expert Rev Respir Med 2009; 3: 245-254.
240. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D.
241. World Health Organization. Global Tuberculosis Control 2011. Geneva, Switzerland, 2011.
242. UNAIDS. Global HIV/AIDS response. Epidemic update and health sector progress towards Universal Access. Progress report 2011. http://whqlibdoc.who. int/publications/2011/9789241502986-eng.pdf
243. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
244. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
245. Kurbatova EV, Taylor A, Gammino VM, et al. Predictors of poor outcomes among patients treated for multidrugresistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) 2012; 92: 397-403.
246. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
247. Leimane V, Dravniece G, Riekstina V, et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; 36: 584-593.
248. Balabanova Y, Nikolayevskyy V, Ignatyeva O, et al. Survival of civilian and prisoner drug-sensitive, multi- and extensive drug- resistant tuberculosis cohorts prospectively followed in Russia. PLoS One 2011; 6: e20531.
249. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54: 1071-1079.
250. Steingart KR, Sohn H, Schiller I, et al. Xpert1 MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1: CD009593.
251. World Health Organization. Xpert MTB/RIF increases timely TB detection among people living with HIV and saves lives. Information note. www.who.int/tb/challenges/hiv/Xpert-TBHIV-Information-Note-final. pdfDatelastupdated:.2013
252. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay - a clinical validation study. PLoS One 2011; 6: e20458.
253. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-1491.
254. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-1501.
255. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-539.
256. Gelmanova IY, Keshavjee S, Golubchikova VT, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703-711.
257. Gelmanova IY, Taran DV, Mishustin SP, et al. Sputnik: a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters. Int J Tuberc Lung Dis 2011; 15: 1373-1379.
258. Isaakidis P, Cox HS, Varghese B, et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One 2011; 6: e28066.
259. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63-80.
260. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
261. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352.
262. Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013; 13: 449-458.
263. World Health Organization. Meeting report of the 3rd Global GLC meeting 17-19 October 2012. Geneva, Switzerland, 2012.
264. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
265. ODonnell MR, Padayatchi N, Kvasnovsky C, et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013; 19: 416-424.
266. Connor S, Foley K, Harding R, et al. Declaration on palliative care and MDR/XDR-TB. Int J Tuberc Lung Dis 2012; 16: 712-713.
267. Harding R, Foley KM, Connor SR, et al. Palliative and end-of-life care in the global response to multidrug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 643-646.
268. World Health Organization. WHO Definition of Palliative Care. www.who.int/cancer/palliative/definition/en/
269. Hospice Palliative Care Association. Guidelines for Providing Palliative Care to Patients with Tuberculosis. www.hospicepalliativecaresa.co.za/pdf/ patientcare/TB-Guidelines-2011.PDFDatelastupdated:May2011.